Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity |
| |
| Authors: | Nicolai Härtel Thomas Klag Benjamin Hanfstein Martin C. Mueller Thomas Schenk Philipp Erben Andreas Hochhaus Paul La Rosée |
| |
| Affiliation: | 1.III. Medizinische Universit?tsklinik,Universit?tsmedizin Mannheim der Universit?t Heidelberg,Mannheim,Germany;2.Klinik f. Innere Medizin II, Abt. f. H?matologie/Onkologie,Universit?tsklinikum Jena,Jena,Germany |
| |
| Abstract: | ![]()
Background Targeted treatment of chronic myelogenous leukemia using imatinib has dramatically improved patient outcome. However, residual disease can be detected in the majority of patients treated with imatinib. Compensatory activation of MAP kinases (MAPK1/2) in response to BCR-ABL-inhibitors has been reported as a potential cytokine-dependent resistance mechanism leading to the rescue of leukemic progenitor cells. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
